{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:57:57Z","timestamp":1790434677355,"version":"4.1.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.colsurfb.2026.115675","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:29:33Z","timestamp":1775150973000},"page":"115675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recent advances in LNP-mRNA vaccines"],"prefix":"10.1016","volume":"265","author":[{"given":"Benjamin J.","family":"Redenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-0659","authenticated-orcid":false,"given":"Yizhou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1645","key":"10.1016\/j.colsurfb.2026.115675_bib1","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"10441","key":"10.1016\/j.colsurfb.2026.115675_bib2","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib3","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1542\/peds.2008-0567","article-title":"Varicella prevention in the United States: a review of successes and challenges","volume":"122","author":"Marin","year":"2008","journal-title":"Pediatrics"},{"issue":"ement_4","key":"10.1016\/j.colsurfb.2026.115675_bib4","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"45","key":"10.1016\/j.colsurfb.2026.115675_bib5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.15585\/mmwr.mm7345a4","article-title":"Progress Toward Measles Elimination \u2014 Worldwide, 2000-2023","volume":"73","author":"Minta","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib6","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.apsb.2023.03.001","article-title":"mRNA delivery in cancer immunotherapy","volume":"13","author":"Zhong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"and C.S. Group, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.colsurfb.2026.115675_bib11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.colsurfb.2026.115675_bib12","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of TWO RNA-Based Covid-19 VACCINE CANDidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.colsurfb.2026.115675_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib15","article-title":"Nanotechnology-based mRNA vaccines","volume":"3","author":"Chen","year":"2023","journal-title":"Nat. Rev. Methods Prim."},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib16","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.1007\/s12274-024-6978-6","article-title":"mRNA medicine: Recent progresses in chemical modification, design, and engineering","volume":"17","author":"Hou","year":"2024","journal-title":"Nano Res."},{"issue":"20","key":"10.1016\/j.colsurfb.2026.115675_bib17","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.colsurfb.2026.115675_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"issue":"22","key":"10.1016\/j.colsurfb.2026.115675_bib21","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","article-title":"Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity","volume":"70","author":"Kreiter","year":"2010","journal-title":"Cancer Res"},{"issue":"5943","key":"10.1016\/j.colsurfb.2026.115675_bib22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1175870","article-title":"Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation","volume":"325","author":"Johnston","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.immuni.2009.07.002","article-title":"The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment","volume":"31","author":"Yu","year":"2009","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri3803","article-title":"A brief history of T cell help to B cells","volume":"15","author":"Crotty","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0008-8749(74)90261-5","article-title":"Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice","volume":"13","author":"Jacobson","year":"1974","journal-title":"Cell Immunol."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib26","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.immuni.2024.10.003","article-title":"Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues","volume":"57","author":"Davis-Porada","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.colsurfb.2026.115675_bib27","article-title":"mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern","author":"Goel","year":"2021","journal-title":"bioRxiv"},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01667363","article-title":"Cationic lipid-mediated transfection in mammalian cells: \u201cLipofection","volume":"15","author":"Felgner","year":"1993","journal-title":"J. Tissue Cult. Methods"},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040359","article-title":"Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines","volume":"9","author":"Thi","year":"2021","journal-title":"Vaccines"},{"issue":"10427","key":"10.1016\/j.colsurfb.2026.115675_bib32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"7607","key":"10.1016\/j.colsurfb.2026.115675_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"16","key":"10.1016\/j.colsurfb.2026.115675_bib35","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"45","key":"10.1016\/j.colsurfb.2026.115675_bib36","doi-asserted-by":"crossref","first-page":"21782","DOI":"10.1039\/C9NR05475H","article-title":"Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant","volume":"11","author":"Yang","year":"2019","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.gt.3300596","article-title":"Time-dependent maturation of cationic liposome-DNA complex for serum resistance","volume":"5","author":"Yang","year":"1998","journal-title":"Gene Ther."},{"issue":"16","key":"10.1016\/j.colsurfb.2026.115675_bib38","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1089\/10430349950016762","article-title":"RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization","volume":"10","author":"Zhou","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.colsurfb.2026.115675_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"34","key":"10.1016\/j.colsurfb.2026.115675_bib40","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib41","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib42","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115675_bib43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib44","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"issue":"5373","key":"10.1016\/j.colsurfb.2026.115675_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.281.5373.78","article-title":"An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery","volume":"281","author":"Koltover","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.colsurfb.2026.115675_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib47","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"36","key":"10.1016\/j.colsurfb.2026.115675_bib48","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"10.1016\/j.colsurfb.2026.115675_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib50","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1093\/infdis\/jiae035","article-title":"Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial","volume":"230","author":"Shaw","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"7823","key":"10.1016\/j.colsurfb.2026.115675_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","article-title":"Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery","volume":"40","author":"Sun","year":"2023","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib53","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"issue":"17-18","key":"10.1016\/j.colsurfb.2026.115675_bib54","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien. Klin. Woche"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Group, Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial.","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"25","key":"10.1016\/j.colsurfb.2026.115675_bib56","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib57","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1\/2 Randomized Trial","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.colsurfb.2026.115675_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib59","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib60","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib61","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.colsurfb.2026.115675_bib62","doi-asserted-by":"crossref","first-page":"ofac206","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults","volume":"9","author":"August","year":"2022","journal-title":"Open Forum Infect. Dis."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib63","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-064748","article-title":"Safety and immunogenicity of an mRNA-based hMPV\/PIV3 combination vaccine in seropositive children","volume":"153","author":"Schnyder Ghamloush","year":"2024","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib64","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"7963","key":"10.1016\/j.colsurfb.2026.115675_bib65","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.colsurfb.2026.115675_bib66","doi-asserted-by":"crossref","first-page":"15231","DOI":"10.1021\/acsnano.2c12584","article-title":"The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology","volume":"17","author":"Ye","year":"2023","journal-title":"ACS Nano"},{"issue":"52","key":"10.1016\/j.colsurfb.2026.115675_bib67","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311752120","article-title":"Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants","volume":"120","author":"Ye","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib68","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115675_bib69","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41564-025-02070-z","article-title":"Challenges and opportunities in mRNA vaccine development against bacteria","volume":"10","author":"Aernout","year":"2025","journal-title":"Nat. Microbiol"},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib70","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115675_bib71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","article-title":"Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines","volume":"18","author":"Han","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.colsurfb.2026.115675_bib72","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.nanolett.2c04883","article-title":"STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2","volume":"23","author":"Zhang","year":"2023","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"npj Vaccin."},{"key":"10.1016\/j.colsurfb.2026.115675_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.colsurfb.2026.115675_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101823","article-title":"and C.S. Team, COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.","volume":"56","author":"Szubert","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib76","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A Thermostable mRNA Vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"issue":"7893","key":"10.1016\/j.colsurfb.2026.115675_bib77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib78","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib79","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib80","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib81","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.colsurfb.2026.115675_bib82","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"6158","key":"10.1016\/j.colsurfb.2026.115675_bib83","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib84","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"npj Vaccin."},{"key":"10.1016\/j.colsurfb.2026.115675_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127589","article-title":"Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus","volume":"63","author":"Shaw","year":"2025","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib86","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"issue":"15","key":"10.1016\/j.colsurfb.2026.115675_bib87","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"and G. Valganciclovir Study, A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.","volume":"346","author":"Martin","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-199937020-00005","article-title":"Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive Volunteers","volume":"37","author":"Brown","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib90","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01603-23","article-title":"Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults","volume":"98","author":"Wu","year":"2024","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib92","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41541-023-00656-4","article-title":"An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection","volume":"8","author":"Bollman","year":"2023","journal-title":"npj Vaccin."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib93","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(20)30393-4","article-title":"and N. Respiratory Virus Global Epidemiology, Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study.","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Glob. Health"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib94","doi-asserted-by":"crossref","first-page":"eadg1036","DOI":"10.1126\/sciadv.adg1036","article-title":"A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium","volume":"9","author":"Kon","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib95","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1038\/s41467-022-33721-y","article-title":"Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes","volume":"13","author":"Mayer","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib96","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-023-00672-4","article-title":"Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccin."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib97","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib98","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.idc.2022.03.004","article-title":"Epidemiology of Lyme Disease","volume":"36","author":"Mead","year":"2022","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib99","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S1473-3099(23)00210-4","article-title":"Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults","volume":"23","author":"Bezay","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115675_bib100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1473-3099(24)00175-0","article-title":"Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies","volume":"24","author":"Bezay","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib101","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1473-3099(24)00372-4","article-title":"Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial","volume":"24","author":"Ghadge","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115675_bib102","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.ymthe.2023.07.022","article-title":"Development of an mRNA-lipid nanoparticle vaccine against Lyme disease","volume":"31","author":"Pine","year":"2023","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib103","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","article-title":"Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in South African adults","volume":"188","author":"Day","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.colsurfb.2026.115675_bib104","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberc. (Edinb. )"},{"issue":"17","key":"10.1016\/j.colsurfb.2026.115675_bib105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01(E) Vaccine to Prevent Tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.colsurfb.2026.115675_bib106","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.colsurfb.2026.115675_bib107","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6230","key":"10.1016\/j.colsurfb.2026.115675_bib108","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.colsurfb.2026.115675_bib109","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"and K.-. investigators, Pembrolizumab versus Ipilimumab in Advanced Melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7793","key":"10.1016\/j.colsurfb.2026.115675_bib110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib112","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"7662","key":"10.1016\/j.colsurfb.2026.115675_bib113","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.colsurfb.2026.115675_bib114","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115675_bib115","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib116","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","article-title":"PGV001, a multi-peptide personalized neoantigen vaccine platform: phase i study in patients with solid and hematologic malignancies in the adjuvant setting","volume":"15","author":"Saxena","year":"2025","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib117","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2004.08.083","article-title":"Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group","volume":"22","author":"Kaufman","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.colsurfb.2026.115675_bib118","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115675_bib119","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"and I.S. Investigators, Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib120","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib121","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000063","article-title":"A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib122","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol."},{"issue":"7953","key":"10.1016\/j.colsurfb.2026.115675_bib123","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy","volume":"615","author":"Puig-Saus","year":"2023","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.colsurfb.2026.115675_bib124","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"7662","key":"10.1016\/j.colsurfb.2026.115675_bib125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.colsurfb.2026.115675_bib126","series-title":"A Phase I\/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer","author":"National Cancer","year":"2019"},{"issue":"8056","key":"10.1016\/j.colsurfb.2026.115675_bib127","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib128","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib129","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115675_bib130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41578-024-00684-z","article-title":"Engineering nanomaterials for glioblastoma nanovaccination","volume":"9","author":"Hameedat","year":"2024","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib131","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","article-title":"Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier","volume":"17","author":"Kuzminich","year":"2024","journal-title":"Nano Res."},{"issue":"33","key":"10.1016\/j.colsurfb.2026.115675_bib132","doi-asserted-by":"crossref","first-page":"eadw0730","DOI":"10.1126\/sciadv.adw0730","article-title":"Lipid nanoparticles for mRNA delivery in brain via systemic administration","volume":"11","author":"Cao","year":"2025","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib133","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/acs.nanolett.4c05186","article-title":"Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain","volume":"25","author":"Han","year":"2025","journal-title":"Nano Lett."},{"issue":"19","key":"10.1016\/j.colsurfb.2026.115675_bib134","doi-asserted-by":"crossref","first-page":"16007","DOI":"10.1021\/jacs.4c16326","article-title":"Furan-Derived Lipid Nanoparticles for Transporting mRNA to the Central Nervous System","volume":"147","author":"Liu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"41","key":"10.1016\/j.colsurfb.2026.115675_bib135","doi-asserted-by":"crossref","first-page":"36106","DOI":"10.1021\/acsnano.4c15013","article-title":"AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism","volume":"19","author":"Sela","year":"2025","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib136","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib137","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"34","key":"10.1016\/j.colsurfb.2026.115675_bib138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8 T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib139","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.molpharmaceut.9b01182","article-title":"The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution","volume":"17","author":"Nakamura","year":"2020","journal-title":"Mol. Pharm."},{"issue":"22","key":"10.1016\/j.colsurfb.2026.115675_bib140","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1021\/jacs.4c00451","article-title":"Multicomponent synthesis of imidazole-based ionizable lipids for highly efficient and spleen-selective messenger RNA delivery","volume":"146","author":"Dong","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"45","key":"10.1016\/j.colsurfb.2026.115675_bib141","doi-asserted-by":"crossref","first-page":"41756","DOI":"10.1021\/jacs.5c13982","article-title":"Fluorinated ionizable lipids for efficient spleen-targeted mRNA delivery in cancer immunotherapy","volume":"147","author":"Zhang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"19","key":"10.1016\/j.colsurfb.2026.115675_bib142","article-title":"A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery","volume":"10","author":"Naidu","year":"2023","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib143","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20210146","article-title":"From structural design to delivery: mRNA therapeutics for cancer immunotherapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Exploration"},{"issue":"10","key":"10.1016\/j.colsurfb.2026.115675_bib144","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41551-025-01511-8","article-title":"Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level","volume":"9","author":"Kang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib145","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib146","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1038\/s41467-021-27434-x","article-title":"Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.colsurfb.2026.115675_bib147","doi-asserted-by":"crossref","first-page":"e202318515","DOI":"10.1002\/anie.202318515","article-title":"Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability","volume":"63","author":"Lei","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.colsurfb.2026.115675_bib148","article-title":"Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines","volume":"34","author":"Wang","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"26","key":"10.1016\/j.colsurfb.2026.115675_bib149","doi-asserted-by":"crossref","first-page":"e202405444","DOI":"10.1002\/anie.202405444","article-title":"One-component cationic lipids for systemic mRNA delivery to splenic T cells","volume":"63","author":"Zhang","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"issue":"32","key":"10.1016\/j.colsurfb.2026.115675_bib150","doi-asserted-by":"crossref","first-page":"28665","DOI":"10.1021\/jacs.5c01389","article-title":"Carbonate-bearing ionizable lipids for mRNA delivery to splenic NK cells","volume":"147","author":"Wu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"6753","key":"10.1016\/j.colsurfb.2026.115675_bib151","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib152","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"issue":"15","key":"10.1016\/j.colsurfb.2026.115675_bib153","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115675_bib154","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acsabm.3c00721","article-title":"Advances in nonviral mRNA delivery materials and their application as vaccines for melanoma therapy","volume":"7","author":"Neill","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115675_bib155","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/acs.nanolett.2c03784","article-title":"ROS-responsive nanoparticle delivery of mRNA and photosensitizer for combinatorial cancer therapy","volume":"23","author":"Zhou","year":"2023","journal-title":"Nano Lett."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib156","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41551-024-01285-5","article-title":"Antitumour vaccination via the targeted proteolysis of antigens isolated from tumour lysates","volume":"9","author":"Zhao","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib157","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41551-018-0284-0","article-title":"Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA","volume":"2","author":"Islam","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib158","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41467-025-57149-2","article-title":"LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment","volume":"16","author":"Xue","year":"2025","journal-title":"Nat. Commun."},{"issue":"47","key":"10.1016\/j.colsurfb.2026.115675_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202207486","article-title":"Nanomaterials-mediated Co-stimulation of toll-like receptors and CD40 for antitumor immunity","volume":"34","author":"Yan","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.colsurfb.2026.115675_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113684","article-title":"Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L\/Flt3L mRNA-mediated dendritic cell activation","volume":"382","author":"Hou","year":"2025","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib161","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41565-023-01453-9","article-title":"Close the cancer\u2013immunity cycle by integrating lipid nanoparticle\u2013mRNA formulations and dendritic cell therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Nat. Nanotechnol."},{"issue":"610","key":"10.1016\/j.colsurfb.2026.115675_bib162","doi-asserted-by":"crossref","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib163","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/1078-0432.CCR-24-1983","article-title":"A Phase I, First-in-human, dose-escalation, expansion trial of cytokine-encoding synthetic mRNA mixture alone or with cemiplimab in advanced solid tumors","volume":"31","author":"Bechter","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"23","key":"10.1016\/j.colsurfb.2026.115675_bib164","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115675_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib166","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib167","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"npj Vaccin."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib168","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115675_bib170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"31","key":"10.1016\/j.colsurfb.2026.115675_bib171","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115675_bib172","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115675_bib173","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201904905","article-title":"Mild innate immune activation overrides efficient nanoparticle-mediated RNA delivery","volume":"32","author":"Lokugamage","year":"2020","journal-title":"Adv. Mater."},{"issue":"26","key":"10.1016\/j.colsurfb.2026.115675_bib174","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115675_bib175","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115675_bib176","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"10278","key":"10.1016\/j.colsurfb.2026.115675_bib177","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526002638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526002638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T02:22:19Z","timestamp":1780798939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526002638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":177,"alternative-id":["S0927776526002638"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115675","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in LNP-mRNA vaccines","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115675"}}